RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jeremy Pomeroy to alpha-MSH

Back to Details
This is a "connection" page, showing publications Jeremy Pomeroy has written about alpha-MSH.
Jeremy Pomeroy
Connection Strength
0.462
alpha-MSH
  1. Argente J, Haqq AM, Schorfheide JL, Touchot N, Huber C, Wiedemann U, Pomeroy J. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity (Silver Spring). 2026 Mar; 34(3):579-587.
    View in: PubMed
    Score: 0.244
  2. Lazareva J, Sisley SR, Brady SM, Smith ACM, Elsea SH, Pomeroy JJ, Roth CL, Sprague JE, Wabitsch M, Garrison J, Yanovski JA. Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome. Obes Res Clin Pract. 2024 Jul-Aug; 18(4):301-307.
    View in: PubMed
    Score: 0.218
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support